Pfizer and Blackstone agree up to $1.5 billion in development funding for monthly GLP-1 obesity candidate berobenatide

Pfizer and Blackstone Life Sciences have agreed a development co-funding arrangement of up to $1.5 billion for investigational once-monthly GLP-1 therapy berobenatide, sharing clinical development risk while Pfizer retains control of the programme.

Pfizer and Blackstone Life Sciences announced a strategic funding agreement on 11 November 2026 under which Blackstone-managed funds will provide up to $1.5 billion through 2028 toward the clinical development of berobenatide, an investigational once-monthly injectable GLP-1 receptor agonist being studied for chronic weight management and obesity-related conditions.

Under the arrangement, Blackstone may receive payments linked to US regulatory approval of monthly injectable berobenatide monotherapy and specified commercial sales milestones, while Pfizer retains the programme and its development responsibilities; the $1.5 billion represents a maximum development funding commitment rather than an acquisition price, guaranteed upfront consideration or regulatory approval.

Field	Content
Article Type	Deals
Pharmaceutical Company	Pfizer
Funding Partner	Blackstone Life Sciences
Funding Source	Blackstone-managed funds
Deal Type	Strategic clinical development co-funding agreement
Announcement Date	11 November 2026
Agreement Status	Announced
Funded Programme	Berobenatide
Drug Development Status	Investigational
Drug Class	GLP-1 receptor agonist
Drug Modality	Injectable medicine
Proposed Dosing Frequency	Once monthly
Therapeutic Area	Obesity and metabolic disease
Primary Development Focus	Chronic weight management
Additional Development Focus	Obesity-related conditions
Maximum Funding Commitment	Up to $1.5 billion
Funding Period	Through 2028
Funding Purpose	Clinical development costs
Funding Structure	Development co-funding with contingent return payments
Funding Provider Consideration	Potential payments linked to regulatory and commercial milestones
Regulatory Payment Trigger	US regulatory approval of monthly injectable berobenatide monotherapy
Commercial Payment Triggers	Specified sales milestones
Commercial Milestone Amounts	Not disclosed in supplied summary
Programme Ownership	Retained by Pfizer
Development Responsibilities	Retained by Pfizer
Acquisition Involved	No
Guaranteed Upfront Acquisition Payment	Not applicable
Regulatory Approval Granted	No
What Happened	Pfizer and Blackstone Life Sciences agreed to share funding and financial exposure associated with berobenatide clinical development.
Why It Matters	The arrangement provides substantial external financing for an obesity programme while allowing Pfizer to retain ownership and development control.
Strategic Significance	Illustrates a risk-sharing financing model for capital-intensive late-stage pharmaceutical development.
Financial Clarification	The up to $1.5 billion figure is a funding commitment through 2028 rather than a purchase price or guaranteed cash payment to Pfizer.
Regulatory Clarification	Berobenatide remains investigational and any future regulatory approval is contingent.
Key Takeaway	Blackstone-managed funds may contribute up to $1.5 billion toward Pfizer's monthly GLP-1 development programme in return for contingent future payments.
What to Watch	Clinical development milestones, efficacy and safety results, US regulatory progress, funding deployment and potential commercial milestone obligations.
Primary Source	Blackstone
Primary Source URL	https://www.blackstone.com/news/press/pfizer-and-blackstone-life-sciences-announce-strategic-funding-agreement-for-obesity-program/
Submitted Source	pharmaphorum
Submitted Source URL	https://pharmaphorum.com/news/blackstone-buys-pfizers-glp-1-drug-development
Relevant Date	11 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com